Article Contents ::
- 1 Details About Generic Salt :: Pioglita
- 2 Main Medicine Class:: Antidiabetic
- 3 (pye-oh-GLI-ta-zone) Actos Tablet: 15 mg Tablet: 30 mg Tablet: 45 mg Class: Antidiabetic Thiazolidinedione Indications Type 2 diabetes, as an adjunct to diet and exercise; also may be used in conjunction with a sulfonylurea, metformin, or insulin. Contraindications Standard considerations. Route/Dosage Initially, PO 15 or 30 mg/day, up to 45 mg/day. If monotherapy is inadequate, consider combinations using same starting dose and adjust accordingly. May be given without regard to meals. Interactions Contraceptives, oral: Oral contraceptives may decrease both hormone components about 30%, potentially reducing contraceptive effectiveness. P450 system: Cytochrome P450 isoform CYP3A4 is partially responsible for pioglitazone metabolism; therefore, other drugs affected by or affecting this system may interact. Lab Test Interferences Mean hemoglobin values may decline 2% to 4%, usually in first 4 to 12 wk of therapy, then stabilize; not associated with hemotologic clinical effects. Adverse Reactions CNS: Headache. METABOLIC: Diabetes mellitus aggravated. RESPIRATORY: Upper respiratory tract infection, sinusitis, pharyngitis. OTHER: Myalgia, tooth disorder, edema. Precautions Pregnancy: Category C. LACTATION: Undetermined. CHILDREN: Safety and efficacy not established. Ovulation: May result in ovulation in premenopausal anovulatory women; recommend contraception. Edema: Use caution. Hepatic function: Related drugs have reported rare hepatotoxicity; monitor liver enzymes and symptoms. PATIENT CARE CONSIDERATIONS Administration/Storage Do not administer to patients with clinical evidence of active liver disease or elevated liver enzymes (ALT above 2.5 × upper limit of normal) or to patients with type 1 diabetes mellitus. Administer dose qd, usually in the morning, with or without food. Store at controlled room temperature. Protect from moisture and humidity. Assessment/Interventions Obtain patient history, including drug history and any known allergies. Note history of liver disease or CHF. Ensure that liver enzymes are determined before starting therapy and periodically during therapy (eg, q 2 mo for first year, then periodically thereafter). Check blood sugar frequently and observe for signs of hypoglycemia and hyperglycemia; report to health care provider. Patient/Family Education Explain name, dose, action, and potential side effects of drug. Advise patient to take qd without regard to meals. Educate patient, family, or caregiver regarding type 2 diabetes and its management. Instruct patient that this drug is not a substitute for diet and exercise and to follow prescribed regimens. Emphasize the importance of regular daily blood glucose monitoring and periodic glycosylated hemoglobin (HbA1c) tests. Advise diabetic patient to carry medical identification (eg, Medi-Alert). Advise patient to report any of the following to the health care provider immediately: nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, yellowing of the skin or eyes. Review symptoms of hypoglycemia and hyperglycemia and action plans to undertake in the event either occur. Instruct patient to report hypoglycemic or hyperglycemic episodes to the health care provider. Advise patient that blood will be drawn to check liver function prior to starting therapy and about every 2 mo for the first year and periodically thereafter. Remind patient to keep appointments. Caution women that drug can cause resumption of ovulation in premenopausal, anovulatory women with insulin resistance. Address adequate contraceptive measures for these women. Advise women to inform health care provider if pregnant, planning on becoming pregnant, or are breastfeeding. Instruct patient not to take prescription or OTC drugs or dietary supplements without consulting health care provider.
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Pioglita
Main Medicine Class:: Antidiabetic
(pye-oh-GLI-ta-zone)
Actos
Tablet: 15 mg
Tablet: 30 mg
Tablet: 45 mg
Class: Antidiabetic
Thiazolidinedione
Indications Type 2 diabetes, as an adjunct to diet and exercise; also may be used in conjunction with a sulfonylurea, metformin, or insulin.
Contraindications Standard considerations.
Route/Dosage
Initially, PO 15 or 30 mg/day, up to 45 mg/day. If monotherapy is inadequate, consider combinations using same starting dose and adjust accordingly. May be given without regard to meals.
Interactions
Contraceptives, oral: Oral contraceptives may decrease both hormone components about 30%, potentially reducing contraceptive effectiveness. P450 system: Cytochrome P450 isoform CYP3A4 is partially responsible for pioglitazone metabolism; therefore, other drugs affected by or affecting this system may interact.
Lab Test Interferences Mean hemoglobin values may decline 2% to 4%, usually in first 4 to 12 wk of therapy, then stabilize; not associated with hemotologic clinical effects.
Adverse Reactions
CNS: Headache. METABOLIC: Diabetes mellitus aggravated. RESPIRATORY: Upper respiratory tract infection, sinusitis, pharyngitis. OTHER: Myalgia, tooth disorder, edema.
Precautions
Pregnancy: Category C. LACTATION: Undetermined. CHILDREN: Safety and efficacy not established. Ovulation: May result in ovulation in premenopausal anovulatory women; recommend contraception. Edema: Use caution. Hepatic function: Related drugs have reported rare hepatotoxicity; monitor liver enzymes and symptoms.
PATIENT CARE CONSIDERATIONS
Administration/Storage
- Do not administer to patients with clinical evidence of active liver disease or elevated liver enzymes (ALT above 2.5 × upper limit of normal) or to patients with type 1 diabetes mellitus.
- Administer dose qd, usually in the morning, with or without food.
- Store at controlled room temperature. Protect from moisture and humidity.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note history of liver disease or CHF.
- Ensure that liver enzymes are determined before starting therapy and periodically during therapy (eg, q 2 mo for first year, then periodically thereafter).
- Check blood sugar frequently and observe for signs of hypoglycemia and hyperglycemia; report to health care provider.
Patient/Family Education
- Explain name, dose, action, and potential side effects of drug.
- Advise patient to take qd without regard to meals.
- Educate patient, family, or caregiver regarding type 2 diabetes and its management.
- Instruct patient that this drug is not a substitute for diet and exercise and to follow prescribed regimens.
- Emphasize the importance of regular daily blood glucose monitoring and periodic glycosylated hemoglobin (HbA1c) tests.
- Advise diabetic patient to carry medical identification (eg, Medi-Alert).
- Advise patient to report any of the following to the health care provider immediately: nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, yellowing of the skin or eyes.
- Review symptoms of hypoglycemia and hyperglycemia and action plans to undertake in the event either occur. Instruct patient to report hypoglycemic or hyperglycemic episodes to the health care provider.
- Advise patient that blood will be drawn to check liver function prior to starting therapy and about every 2 mo for the first year and periodically thereafter. Remind patient to keep appointments.
- Caution women that drug can cause resumption of ovulation in premenopausal, anovulatory women with insulin resistance. Address adequate contraceptive measures for these women.
- Advise women to inform health care provider if pregnant, planning on becoming pregnant, or are breastfeeding.
- Instruct patient not to take prescription or OTC drugs or dietary supplements without consulting health care provider.
PATIENT CARE CONSIDERATIONS
Drugs Class ::
(pye-oh-GLI-ta-zone) |
Actos |
Tablet: 15 mg |
Tablet: 30 mg |
Tablet: 45 mg |
Class: Antidiabetic |
Thiazolidinedione |
Indications for Drugs ::
Indications Type 2 diabetes, as an adjunct to diet and exercise; also may be used in conjunction with a sulfonylurea, metformin, or insulin.
Drug Dose ::
Route/Dosage
Initially, PO 15 or 30 mg/day, up to 45 mg/day. If monotherapy is inadequate, consider combinations using same starting dose and adjust accordingly. May be given without regard to meals.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category C. LACTATION: Undetermined. CHILDREN: Safety and efficacy not established. Ovulation: May result in ovulation in premenopausal anovulatory women; recommend contraception. Edema: Use caution. Hepatic function: Related drugs have reported rare hepatotoxicity; monitor liver enzymes and symptoms.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CNS: Headache. METABOLIC: Diabetes mellitus aggravated. RESPIRATORY: Upper respiratory tract infection, sinusitis, pharyngitis. OTHER: Myalgia, tooth disorder, edema.
Drug Mode of Action ::
(pye-oh-GLI-ta-zone) |
Actos |
Tablet: 15 mg |
Tablet: 30 mg |
Tablet: 45 mg |
Class: Antidiabetic |
Thiazolidinedione |
Drug Interactions ::
Interactions
Contraceptives, oral: Oral contraceptives may decrease both hormone components about 30%, potentially reducing contraceptive effectiveness. P450 system: Cytochrome P450 isoform CYP3A4 is partially responsible for pioglitazone metabolism; therefore, other drugs affected by or affecting this system may interact.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note history of liver disease or CHF.
- Ensure that liver enzymes are determined before starting therapy and periodically during therapy (eg, q 2 mo for first year, then periodically thereafter).
- Check blood sugar frequently and observe for signs of hypoglycemia and hyperglycemia; report to health care provider.
Drug Storage/Management ::
Administration/Storage
- Do not administer to patients with clinical evidence of active liver disease or elevated liver enzymes (ALT above 2.5 × upper limit of normal) or to patients with type 1 diabetes mellitus.
- Administer dose qd, usually in the morning, with or without food.
- Store at controlled room temperature. Protect from moisture and humidity.
Drug Notes ::
Patient/Family Education
- Explain name, dose, action, and potential side effects of drug.
- Advise patient to take qd without regard to meals.
- Educate patient, family, or caregiver regarding type 2 diabetes and its management.
- Instruct patient that this drug is not a substitute for diet and exercise and to follow prescribed regimens.
- Emphasize the importance of regular daily blood glucose monitoring and periodic glycosylated hemoglobin (HbA1c) tests.
- Advise diabetic patient to carry medical identification (eg, Medi-Alert).
- Advise patient to report any of the following to the health care provider immediately: nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, yellowing of the skin or eyes.
- Review symptoms of hypoglycemia and hyperglycemia and action plans to undertake in the event either occur. Instruct patient to report hypoglycemic or hyperglycemic episodes to the health care provider.
- Advise patient that blood will be drawn to check liver function prior to starting therapy and about every 2 mo for the first year and periodically thereafter. Remind patient to keep appointments.
- Caution women that drug can cause resumption of ovulation in premenopausal, anovulatory women with insulin resistance. Address adequate contraceptive measures for these women.
- Advise women to inform health care provider if pregnant, planning on becoming pregnant, or are breastfeeding.
- Instruct patient not to take prescription or OTC drugs or dietary supplements without consulting health care provider.